Search clinical trials for: NNZ-2591

Total 276 results

Neuren Pharmaceuticals Limited

Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

Healthy Volunteers

Australia
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) (PTHS-001)

Pitt Hopkins Syndrome

United States
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001)

Prader-Willi Syndrome

United States
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome (AS-001)

Angelman Syndrome

Australia
Neuren Pharmaceuticals Limited

Active, not recruiting

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) (PMS-001)

Phelan-McDermid Syndrome

United States
Minervax ApS
Simbec-Orion Group

Enrolling by invitation

A Follow up Study of Group B Streptococcus Vaccine (GBS-NN/NN2 Vaccine) in Healthy Volunteers

Group B Streptococcus Infection

United Kingdom
Minervax ApS

Completed

Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine

Group B Streptococcus Infection

United Kingdom
Minervax ApS
Simbec Research

Completed

Group B Streptococcus Vaccine in Healthy Females (MVX0002)

Group B Strep Infection

United Kingdom
Minervax ApS
Iqvia Pty Ltd

Active, not recruiting

Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

Group B Streptococcal Infections

Belgium
Minervax ApS
European and Developing Countries Clinical Trials Partnership (EDCTP)

Completed

Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV

Group B Streptococcal Infection

South Africa, Uganda
Purdue University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effects of Food Form on Cephalic Phase Responses

Overweight | Obese

United States
Minervax ApS
Larix A/S

Completed

Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women

Group B Streptococcal Infection

Denmark, United Kingdom, South Africa
University of Nevada, Las Vegas

Recruiting

Ostomy Primary Closure With 0.1% Betaine/0.1% Polyhexanide Wound Irrigation Compared to Pursestring Closure

Colorectal Disorders | Surgical Site Infection | Wound Surgical

United States
Neuren Pharmaceuticals Limited

Completed

Safety Study of NNZ-2566 in Healthy Female Subjects

Brain Injuries, Traumatic

Australia
Neuren Pharmaceuticals Limited

Completed

Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration

Brain Injuries, Traumatic

Australia
Zhejiang ACEA Pharmaceutical Co. Ltd.

Recruiting

A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

AML, Adult

China
TYK Medicines, Inc

Active, not recruiting

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

NSCLC | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

China
TYK Medicines, Inc

Recruiting

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

Healthy Volunteers

China
Boehringer Ingelheim

Completed

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Pulmonary Disease, Chronic Obstructive

Germany
Weill Medical College of Cornell University

Completed

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Gliomas

United States
Weill Medical College of Cornell University

Completed

Neoadjuvant J591 Treatment for Prostate Cancer

Prostate Cancer

United States
Addpharma Inc.

Not yet recruiting

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Hypertension,Essential

Korea, Republic of
TYK Medicines, Inc

Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NSCLC | EGFR Activating Mutation

China
TYK Medicines, Inc

Completed

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

NSCLC

China
Loma Linda University

Completed

Non-pharmacological Interventions for Procedural Pain in Premature Neonates

Prevention of Procedural Pain | Reduction of Procedural Pain | Biochemical Effects of Oral Dextrose

United States
Acibadem University

Completed

Non-Nutritive Sucking vs Non-Nutritive Sucking Combined With Breast Milk on the Neonatal Comfort

Infant, Premature

Turkey
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
NervGen Pharma

Recruiting

NVG-291 in Spinal Cord Injury Subjects

Spinal Cord Injuries | Chronic Spinal Cord Injury | Subacute Spinal Cord Injury

United States
Merck Sharp & Dohme LLC

Terminated

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

Coronavirus Disease (COVID-19)

United States, Austria, Belgium
Novo Nordisk A/S

Completed

A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Anza Therapeutics, Inc.

Terminated

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Chronic Hepatitis C

United States
Akros Pharma Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension (RELIEF-PAH)

Pulmonary Arterial Hypertension
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping (DELIVER)

Duchenne Muscular Dystrophy (DMD)

United States, Belgium, Canada, United Kingdom, Spain, Australia, Italy
Ronald M Burch MD PhD

Completed

Safety and Tolerability of GATE-251 in Normal Human Volunteers

Major Depressive Disorder
Neuren Pharmaceuticals Limited

Terminated

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

Concussion

United States
Novo Nordisk A/S

Completed

Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Neuren Pharmaceuticals Limited
rettsyndrome.org

Completed

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

Rett Syndrome

United States
Weill Medical College of Cornell University

Completed

Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

Prostate Cancer

United States
The Dial Corporation
TKL Research, Inc.; Hill Top Research

Completed

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

Common Cold

United States
Akros Pharma Inc.

Completed

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Diabetes Mellitus

United States
Neuronascent, Inc.
National Institute on Aging (NIA)

Completed

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

Alzheimer Disease

United States
NervGen Pharma

Completed

A Phase I Safety Study of NVG-291 in Healthy Adults

Spinal Cord Injury

Australia
Bayer

Completed

Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.

Pulmonary Disease, Chronic Obstructive | Hypertension, Pulmonary

Germany
Equillium

Withdrawn

Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

Alopecia Areata | Alopecia Totalis | Alopecia Universalis
Hoya Surgical Optics, Inc.

Completed

Comparison of the Hoya Surgical Optics (HSO) iSert 251 Posterior Chamber Aspheric Aphakic Intraocular Lens to Historical / Literature Controls.

Cataract | Aphakia

United States
Bioniz Therapeutics

Completed

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

LGL Leukemia | CTCL

United States
Novo Nordisk A/S

Completed

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Janssen Research & Development, LLC

Completed

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Inflammation | Crohn's Disease

Belgium, France, Israel, Hungary, Russian Federation, Poland, Canada, United States
Innate Pharma

Completed

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
TYK Medicines, Inc

Completed

A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers

Healthy Volunteers

China

Search clinical trials for: NNZ-2591

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations